A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.

Also called NCT01970046

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01970046
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01970046. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Intervention (Drug)
Placebo/Metformin
Intervention (Drug)
SP2086 50 mg b.i.d/Metformin
Intervention (Drug)
SP2086 50 mg q.d./Metformin
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01970046
Content hash
9b6e8059a2f1583f795f613e2ee3770e00248450f1c1b1c838e7997366bc51b9